United States set
language
Menu Shopping cart $0 Search

References to acSDKP

  • Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Menard J. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension. 1999 Mar;33 (3):879-86
  • Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996 Feb 1;97 (3):839-44
  • Struthers AD, MacFadyen R, Fraser C, Robson J, Morton JJ, Junot C, Ezan E. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol. 1999 Dec;34 (7):2072-7